

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山医药集团股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 00874)

## **ANNOUNCEMENT ON THE PROGRESS OF CONNECTED TRANSACTION CAPITAL INCREASE IN BAIYUNSHAN BIOLOGICAL**

Reference is made to the announcement of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 28 May 2025 (the “**Announcement**”) in relation to the connected transaction involving the capital increase in Baiyunshan Biological. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that on 30 June 2025, the Company entered into the Capital Increase Agreement with the GP Venture Capital Fund, Guangzhou Time Honored Brand Fund, GP Industrial Investment Fund, State Owned Assets M&A Fund, Bai Di Biological and Baiyunshan Biological, which took effect on the same date. The principal terms of the Capital Increase Agreement remain unchanged. The principal terms of the Capital Increase Agreement and details of the Capital Increase were set out in the Announcement.

Upon completion of the Capital Increase, the Company’s direct and indirect equity interest in Baiyunshan Biological remains unchanged at 50.00%. Baiyunshan Biological remains a subsidiary of the Company and its financial results continue to be consolidated into the Company’s financial statements.

The Board of

**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 30 June 2025

*As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Ms. Cheng Ning, Mr. Cheng Hongjin, Mr. Tang Heping and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.*